Regional Variability in Botulinum Toxin Type A Practices: A Latin American Survey on Dosing, Preferences, and Clinical Outcomes

Background Regional practices for botulinum toxin type A (BoNT‐A) in Latin America remain underexplored. This study characterizes dosing, brand preferences, and clinical outcomes across 12 countries. Objective To characterize regional variations in BoNT‐A dosing, brand preferences, and clinical outcomes for upper facial treatments. Materials and Methods A cross‐sectional survey of 107 practitioners across 12 Latin American countries (March 2025) analyzed dosing (Speywood/International Units), duration, adverse events, and brand preferences using descriptive statistics. Results Participants primarily practiced in Colombia (65.4%), Mexico (7.5%), and Central America (4.7%). AbobotulinumtoxinA required higher doses (total upper face: 114.98 ± 24.32 Speywood units) versus IncobotulinumtoxinA (66.36 ± 10.12 IU) and OnabotulinumtoxinA (62.94 ± 7.36 IU). Duration was comparable across brands (12.1–14.3 weeks). Regional preferences included AbobotulinumtoxinA in Brazil (55%) and IncobotulinumtoxinA in Mexico (48%), driven by cost or precision. Adverse events were transient (headache: 58.2%, ptosis: 12.2%). Conclusion Latin American practitioners balance cost‐effectiveness and precision, with standardized dosing reflecting regional expertise. Long‐term safety studies are warranted.